Liver Health Supplements Market Size Worth $948.61 Million By 2025

The global liver health supplements market size is expected to reach USD 948.61 million by 2025, exhibiting a CAGR of 4.32% over the forecast period, according to a new report published by Grand View Research, Inc. The changing lifestyle pattern has led to an increase in the consumption of fast food and alcohol, leading to the high prevalence of liver diseases including liver cancer and fatty liver disease. As per the Centers for Disease Control & Prevention (CDC), in U.S. liver disease was diagnosed in nearly 4.5 million adults in 2018. The rising prevalence of liver diseases has increased concerns about liver health, thereby a surge in adoption of liver health supplements.

Various initiatives carried out by public and private organizations to increase awareness about liver health is contributing to the market growth. For instance, in March 2019, Amsety, a nutrition company along with Fatty Liver Foundation launched the Kiss & Click campaign. The campaign is designed to increase awareness regrading liver health and fatty liver disease. The British Liver Trust runs campaigns to promote early diagnosis and intervention along with increasing awareness about all types of liver diseases. Moreover, the Institute of Liver and Biliary Sciences (ILBS) based in Delhi, India undertakes several campaigns to create awareness about hepatitis.

Increase in number of liver supplements launches by the manufacturers is boosting the availability and accessibility of liver health supplements. For instance, in March 2017, Gaia Herbs launched a line of products, Mushroom+Herbs Collection. It included five products, namely, Everday Immune, Mental Clarity, Reishi+Turmeric, Cordyceps+, and Liver Defense. In December 2016, Livwell Products LLC launched drinkSMART, a hangover and liver supplement with vitamins.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/liver-health-supplements-market

Further key findings from the report suggest:

In 2018, herbal supplements segment held the largest market share in terms of revenue, owing to huge usage of herbal supplements in preventing liver health
Capsules segment accounted for the largest revenue share of the liver health supplements market based on dosage form in 2018
Based on geography, Asia Pacific held the largest revenue share in 2018. Adoption of preventive health supplements is witnessing lucrative growth with increase in literacy and disposable income among middle-class population
Key market players include The Himalaya Drug Company; Natures Craft; Swisse; Thompson’s (Integria Healthcare); Enzymedica; Nature’s Bounty; Jarrow Formulas, Inc.; NOW Foods; Irwin’s Natural; Gaia Herbs; and NUTRALife

Grand View Research has segmented the global liver health supplements market on the basis of product, dosage form, and region:

Liver Health Supplements Product Outlook (Revenue, USD Million, 2014 – 2025)

Vitamin & Minerals
Herbal Supplements
Others

Liver Health Supplements Dosage Form Outlook (Revenue, USD Million, 2014 – 2025)

Capsules
Tablets
Liquid
Powder
Others

Liver Health Supplements Regional Outlook (Revenue, USD Million, 2014 – 2025)

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- Spain
- Italy
- France
- Russia
Asia Pacific
- China
- Japan
- India
- Australia
- Singapore
- South Korea
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Table of Content

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.2 Market Definition
1.3 Research Methodology
1.3.1 Information Procurement
1.3.1.1 Purchased database:
1.3.1.2 GVR’s internal database
1.3.2 Primary Research:
1.4 Research Scope and Assumptions
1.5 List to Data Sources
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
2.4 Global Liver Health Supplements Market Snapshot
Chapter 3 Global Liver Health Supplements Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook:
3.1.2. Related/Ancillary Market
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.4 Industry Challenges
3.5 Global Liver Health Supplements Market Analysis Tools
3.5.1 Industry Analysis – Porter’s
3.5.1.1 Bargaining power of the suppliers
3.5.1.2 Bargaining power of the buyers
3.5.1.3 Threats of substitution
3.5.1.4 Threats from new entrants
3.5.1.5 Competitive rivalry
3.5.2 PEST Analysis
3.5.2.1 Political Landscape
3.5.2.2 Economic and Social Landscape
3.5.2.3 Technology Landscape
3.5.3 Major Deals & Strategic Alliances Analysis

Continue………..

Amyotrophic Lateral Sclerosis Treatment Market to Witness Growth Acceleration During 2019 to 2026

The global amyotrophic lateral sclerosis treatment market size is expected to reach USD 885.5 million by 2026, according to a new report by Grand View Research. Some of the key factors driving the market include growing awareness about ALS, increasing incidence rate, and rising geriatric population. However, the cost associated with ALS treatment is high, which may hinder the market growth during the forecast period.

Currently, no cure is available for ALS and treatments such as medications and stem cell therapies can only help to slow down the disease progression, manage the symptoms, and prevent unnecessary complications. Furthermore, inclination towards a sedentary lifestyle among the geriatric population increases the risk of developing the disorder that increases the demand for new targeted treatment options and therapeutic approaches. According to the U.S. Department of Health Resources & Services, the estimated prevalence of amyotrophic lateral sclerosis in the U.S. was 5.2 per 100,000 people and 16,583 cases of ALS were reported in 2015.

Among the treatments, the medications acquired the largest market share in 2018 and is expected to dominate the ALS market over the forecast period. Currently, only two drugs have been approved for use in ALS treatment, Rilutek (riluzole) and Radicava (edaravone). Nuedexta (dextromethorphan/quinidine) in another drug used in ALS treatments, however, it has been approved to treat the pseudobulbar affect (PBA), a comorbidity of ALS. North America held the leading position in the amyotrophic lateral sclerosis market in 2018, while Asia Pacific is projected to grow the fastest among all regions through the forecast period.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/amyotrophic-lateral-sclerosis-treatment-market

Further Key Findings From the Study Suggest:

Medications held the largest market share in the treatment segment. Although, there is no cure for ALS, the approved medications such as riluzole and edaravone help in managing symptoms and delaying the disease progression.
Stem cell therapy is expected to demonstrate the highest CAGR among the treatment over the forecast period due to the increasing demand for new approaches and advanced treatment options
Asia Pacific regional market is projected to demonstrate the fastest growth during the forecast period due to rising disposable income and improving healthcare infrastructure
Some of the major companies operating in this market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.

Grand View Research has segmented the ALS treatment market report on the basis of treatment, distribution channel, and region:

Treatment Outlook (Revenue, USD Million, 2015 – 2026)

Medication
Stem Cell Therapy
Others

Distribution Channel Outlook (Revenue, USD Million, 2015 – 2026)

Hospital Pharmacies
Retail Pharmacies
Others

Regional Outlook (Revenue, USD Million, 2015 – 2026)

North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Russia
Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Table of Content

Chapter 1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Amyotrophic Lateral Sclerosis Treatment Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.2 Market Restraint Analysis
3.4.3 Industry challenges

Continue……….

Neglected Tropical Disease Treatment Market Worth $1.9 Billion By 2026

The global neglected tropical disease (NTD) treatment market size is expected to reach USD 1.9 billion by 2026, expanding at a CAGR of 5.5% during the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of neglected tropical diseases is considered to be the vital impact rendering driver.

According to the data published in the WHO in 2018, T.B. Gambiense is endemic in 24 countries of Central and West Africa. This caused around 98% of reported cases of sleeping sickness. Furthermore, according to the CDC, around 400 people are infected annually by dengue.

Moreover, according to the statistics published in the WHO in 2019, more than 1.5 billion or 24% of the world’s population are infected with soil-transmitted helminthiases. These infections are distributed widely in tropical and subtropical areas majorly occurring in America, sub-Saharan Africa, East Asia, and China.

Presence of pipeline vaccines and drugs is also considered to be one of the major factors driving the market growth over the forecast period. For instance, Bayer AG is developing Nifurtimox (BAYA2502), currently under phase III clinical trials for the treatment of Chagas disease. Furthermore, Johnson & Johnson Services Inc. is developing Bedaquiline 200mg monotherapy regimen which is under phase II clinical trials for the treatment of leprosy and the study is estimated to be completed in 2021.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/neglected-tropical-disease-treatment-market

In addition, Instituto Butantan and Merck & Co., Inc. collaborated to develop vaccines against dengue in 2018. The Instituto Butantan is developing a dengue vaccine candidate in Brazil, TV003, which is in an ongoing Phase III clinical trial. Merck & Co., Inc. will provide funds to Instituto Butantan for its development.

Presence of key players such as F. Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Eisai Co. Ltd., Sanofi, Astellas Pharma, Takeda Pharmaceutical Company Limited, and Gilead Sciences is expected to fuel to the overall market growth. Involvement of these players in new product development is considered to be the contributing factor for the NTD treatment market.

Further key findings from the report suggest:

Dengue held the largest segment share in 2018 owing to its increasing prevalence rate
Buruli ulcer is estimated to be the fastest growing segment over the forecast period owing to rising awareness about the disease
In 2018, drugs were anticipated to be the largest product type segment
Vaccines are estimated to be the fastest growing segment over the forecast period due to strong presence of pipeline products
Asia Pacific dominated the neglected tropical disease treatment market in 2018
Latin America is estimated to witness the fastest growth over the forecast period
MEA held the second largest regional share in 2018 due to increasing burden of neglected tropical diseases in this region

Grand View Research has segmented the global neglected tropical disease treatment market based on disease, product type and region:

Neglected Tropical Disease Treatment Disease Form Outlook (Revenue, USD Million; 2015 – 2026)

Dengue
Rabies
Trachoma
Buruli ulcer
Yaws
Leprosy
Chagas disease
Human African trypanosomiasis (sleeping sickness)
Leishmaniases
Soil-transmitted helminthiases
Others

Neglected Tropical Disease Treatment Disease Product Type Outlook (Revenue, USD Million; 2015 – 2026)

Drugs
Vaccines

Neglected Tropical Disease Treatment Disease Regional Outlook (Revenue, USD Million; 2015 – 2026)

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
Asia Pacific
- Japan
- China
- India
- Indonesia
- Singapore
- Philippines
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Bolivia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Nigeria
- Ghana
- Zimbabwe

Table of Content

Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
  1.2. Information procurement
1.2.1. Purchased database
  1.2.2. GVR’s internal database
  1.2.3. Secondary sources & third party perspectives
  1.2.4. Primary research
  1.3. Information analysis
  1.3.1. Data analysis models
  1.4. Market formulation & data visualization
  1.5. Data validation & publishing
Chapter 2. Executive Summary
  2.1. Market Outlook
  2.2. Segment Outlook
  2.3. Competitive Insights
Chapter 3. Neglected Tropical Disease Treatment Market Variables, Trends & Scope
  3.1. Market Lineage outlook
  3.1.1. Parent market outlook
  3.1.2. Related/ancillary market outlook
  3.2. Penetration & Growth Prospect Mapping
  3.3. Reimbursement Framework
  3.4. Market Dynamics

Continue……….

Organ Transplant Immunosuppressant Drugs Market Worth $5.88 Billion By 2026

The global organ transplant immunosuppressant drugs market size is expected to reach USD 5.88 billion by 2026, registering a CAGR of 3.3% during the forecast period, according to a new report by Grand View Research. Growing patient population requiring organ transplantations and increasing approval of novel products are the factors driving the market growth. However, the high procedural cost of transplantations, the disproportion in the supply and demand for organs, and uncertain reimbursement scenario are the major factors restraining the market growth.

According to the Health Resources & Services Administration and the U.S. Department of Health and Human Services, more than 113,000 people were in need of transplants as of January 2019 and 36,528 transplants were performed in 2018. Hence, there is huge demand for organ transplants that will further boost the market. Kidney transplant held the largest market share in the transplant segment and is expected to retain its leading position through the forecast period. This can be attributed to increasing demand and comparatively better availability of kidneys than other organs.

Among the drug classes, the calcineurin inhibitors are expected to dominate the global organ transplant immunosuppressant drugs market through the forecast period. There are two drugs in this drug class, Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). Although these effective immunosuppressants have been used in kidney transplant recipients for more than 20 years, they hold extensive toxicity profiles. Asia Pacific is expected to show the highest CAGR, while North America is expected to hold the largest share during the forecast period.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/organ-transplant-immunosuppressant-drugs-market

Further Key Findings From the Study Suggest:

Calcineurin inhibitors are expected to command the largest market share in the drug class segment. Calcineurin inhibitors inhibit the activation action of T-cells of the immune system by the enzyme calcineurin.
Calcineurin inhibitors such as tacrolimus and cyclosporine are the cornerstone of immunosuppression for kidney transplantation. In more than 85% cases of kidney transplant, tacrolimus is prescribed as a part of the patients’ maintenance immunosuppressive regimen.
Kidney transplant is expected to maintain its dominance through the forecast period due to the increasing demand for kidney replacement procedures
Asia Pacific regional market is expected to demonstrate the fastest growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare infrastructure, and increasing demand for organ transplantations in the region
Key players operating in this space include Astellas Pharma, Inc., Sanofi Genzyme, Accord Healthcare Ltd., Novartis AG, Mylan Laboratories, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Veloxis Pharmaceuticals A/S, and Bristol-Myers Squibb Company.

Grand View Research has segmented the organ transplant immunosuppressant drugs market report on the basis of drug class, transplant type, distribution channel, and region:

Organ Transplant Immunosuppressant Drugs Drug Class Outlook (Revenue, USD Million, 2015 – 2026)

Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitor
Steroids
Antibodies

Organ Transplant Immunosuppressant Drugs Transplant Type Outlook (Revenue, USD Million, 2015 – 2026)

Kidney
Liver
Heart
Lung
Pancreas
Other

Organ Transplant Immunosuppressant Drugs Distribution Channel Outlook (Revenue, USD Million, 2015 – 2026)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Organ Transplant Immunosuppressant Drugs Regional Outlook (Revenue, USD Million, 2015 – 2026)

North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Russia
Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Table of Content

Chapter 1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Organ Transplant Immunosuppressant Drugs Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Market Dynamics

Continue……….

Missouri Medical Cannabis Market Size Worth $102.4 Million By 2026

The Missouri medical cannabis market size is estimated to be valued at USD 102.4 million in 2026 and is predicted to register a lucrative CAGR of 22.0% over the forecast period, according to a new study by Grand View Research, Inc. Legalization of marijuana for medical applications and growing number of patients qualifying for the same is expected to boost the market in Missouri.

Based on product type, the market is divided into buds, oil, and tinctures. The buds segment is anticipated to hold the largest market share in 2020 with a revenue of USD 20.6 million. Buds being the primary plant product, can be used readily without any processing, which makes it relatively affordable for low-income patients. Moreover, easy availability of buds as compared to other cannabis products is further anticipated to increase their adoption in the state.

Based on application, the chronic pain segment is expected to dominate the Missouri market in 2020 owing to a large patient pool. On the other hand, the mental disorder application is expected to witness fastest growth over the forecast period owing to increasing number of patients suffering from neurological conditions such as anxiety disorder, depression, and Alzheimer’s disease. For instance, according to the Missouri Foundation for Health, around 110,000 people over 65 years and above were suffering from Alzheimer’s disease in 2010 and the number is expected to increase to 130,000 by the end of 2025.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/missouri-medical-cannabis-market

Further key findings from the report suggest:

Buds are anticipated to dominate the Missouri medical cannabis market in 2020, as they can be readily used by patients for smoking. This helps alleviate chronic pain associated with various ailments
The oil segment is anticipated to witness the fastest growth by 2026 owing to increasing adoption of oil as a healthier alternative to smoking marijuana
The chronic pain application segment is anticipated to remain the dominant throughout the forecast period thanks to increasing patient pool

Grand View Research has segmented the Missouri medical cannabis market based on product type and medical application:

Missouri Medical Cannabis Product Type Outlook (Revenue, USD Million, 2020 – 2026)

Buds
Oils
Tinctures

Missouri Medical Cannabis Medical Application Outlook (Revenue, USD Million, 2020 – 2026)

Chronic Pain
Mental Disorders
Cancer
Others

Table of Content

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List to Data Sources
Chapter 2 Executive Summary
Chapter 3 Missouri Medical Cannabis Market: Opportunity Analysis
3.1 Opportunity Analysis
Chapter 4 Missouri Medical Cannabis Market, By Product Type, 2020 to 2026
Chapter 5 Missouri Medical Cannabis Market, By Medical Application, 2020 to 2026
Chapter 6 SWOT Analysis
6.1 Strengths
6.2 Weakness
6.3 Opportunities
6.4 Threats

Continue……….

Vaginitis Therapeutics Market likely to grow at CAGR of 8.4% from 2018 to 2025

The global vaginitis therapeutics market size is expected to reach USD 4.21 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to expand at a CAGR of 8.4% during the forecast period. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/vaginitis-therapeutics-market

Further key findings from the study suggest:

Anti-bacterial segment led the market in 2017 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
Hormone is expected to witness lucrative growth with a CAGR of 9.1% over the forecast period due to the presence of pipeline products and rising adoption of products
Prescription type held the largest market share in 2017, in terms of revenue. The segment was valued at USD 1.14 billion owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
Over the counter is expected to be the fastest-growing type in the coming years with a CAGR of 8.7% due to increasing number of FDA approvals for the treatment of mild vaginitis
North America is estimated to be the largest regional market. It was the dominant region in 2017, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
Asia Pacific is expected to be the fastest-growing region registering a lucrative CAGR over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.
Key players in the vaginitis therapeutics market are Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company
Most of these companies focus on strategic initiatives, such as collaborations, M&A, and product portfolio expansion. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to expand its product portfolio.

Grand View Research has segmented the global vaginitis therapeutics market on the basis of product, type, and region:

Vaginitis Therapeutics Product Outlook (Revenue, USD Million, 2014 – 2025)

Anti-fungal
Anti-bacterial
Hormone

Vaginitis Therapeutics Type Outlook (Revenue, USD Million, 2014 – 2025)

Over-The-Counter (OTC)
Prescription (Rx)

Vaginitis Therapeutics Regional Outlook (Revenue, USD Million, 2014 – 2025)

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
Asia Pacific
- Japan
- China
Latin America
- Brazil
- Mexico
MEA
- South Africa

Table of Content

Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of vaginitis
3.1.1.2 Rising R & D activities for vaginitis therapeutics
3.1.1.3 Changing lifestyle pattern of women
3.1.2 Market restraint analysis
3.1.2.1 Availability of alternative or natural remedies
3.2 Vaginitis Therapeutics – SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.3 Industry Analysis – Porter’s

Continue……….

Sickle Cell Disease Treatment Market Worth $5.5 Billion by 2023 | CAGR: 14.3%

The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by Grand View Research, Inc., exhibiting a 14.3% CAGR during the forecast period. Several factors such as increase in investments for R&D, growing target population, and favorable government initiatives are anticipated to drive the market.

Currently available treatments for sickle cell disease (SCD) usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplant, and pharmacotherapy. Although bone marrow transplant is the only potentially curative treatment, it is recommended only to a small percentage of patients. The market has only two approved products—hydroxyurea and Endari.

High unmet medical needs, strong pipeline, and growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for SCD has increased owing to unavailability of a permanent cure and risks associated with bone marrow transplant.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/sickle-cell-disease-treatment-market

Expected launch of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel is projected to drive the sickle cell disease market during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Further key findings from the report suggest:

Currently, 20 to 25 million people worldwide are reportedly living with sickle cell disease and about 300,000 infants are born annually with the disease
U.S. dominated the global market and is projected to maintain its position through 2023, owing to rise in incidence of diseases and launch of promising pipeline candidates
Among treatments, blood transfusion held the largest share in 2017, followed by pharmacotherapy. However, it is anticipated that pharmacotherapy will lead the market by 2023, supported by a strong pipeline and several promising drug launches
Emmaus Medical, Global Blood Therapeutics, bluebird bio, Pfizer, and Novartis are some of the key players operating in this market
Emmaus Medical is projected to dominate the SCD pharmaceutical market in 2023, supported by strong sales of Endari
Currently, 37 pipeline drugs are in various clinical development stages and significant sales contribution is expected from promising candidates such as voxelotor (Global Blood Therapeutics), crizanlizumab (Novartis), Altemia (Sancilio), and rivipansel (Pfizer).

Grand View Research has segmented the global sickle cell disease treatment market based on treatment and country:

Sickle Cell Disease Treatment Outlook (Revenue, USD Million, 2017 – 2023)

Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

Sickle Cell Disease Country Outlook (Revenue, USD Million, 2017 – 2023)

U.S.
U.K.
Germany
Spain
France
Italy
Japan

Table of Content

Chapter 1 Research Methodology
1.1 Information Procurement
  1.2 Information or Data Analysis
  1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
  3.1 Disease Primer
  3.1.1 Types
3.1.1.1 Genotypic variants
  3.1.1.2 Phenotypic variants
  3.1.2 Diagnosis
  3.1.3 Current Treatment
  3.2 Epidemiology
  3.2.1 U.S.
  3.2.2 Japan
  3.2.3 Germany
  3.2.4 U.K.
  3.2.5 France
  3.2.6 Italy
  3.2.7 Spain
  3.2.8 RoW Continue………..

Artemisinin Combination Therapy Market Worth $697.9 Million By 2025

The global artemisinin combination therapy (ACT) market size is expected to reach USD 697.9 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. Rising adoption rate of ACTs coupled with growing government initiatives to combat malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.

Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.

Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.

For Latest research study :@ https://www.grandviewresearch.com/industry-analysis/artemisinin-combination-therapy-act-market

WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies, because parasites have developed resistance to these medicines.

Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.

Further key findings from the report suggest:

AL was the largest segment in 2017 due to the fact that it was the first ACT to be marketed and prequalified by WHO for its efficacy, safety, and quality. It is available in more than 60 countries and is the only ACT approved by U.S. FDA
MEA held the largest share in the market for ACTs due to growing initiatives by government and non-government organizations to raise awareness
Asia Pacific also held a prominent position in the market owing to factors such as large production base of artemisinin herbs coupled with rising access to ACT in this region
Major players operating in the market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals
Key players are adopting different strategies to increase their market share such as increasing geographic presence, R & D, new product development, and indication extension.

Grand View Research has segmented the global artemisinin combination therapy market on the basis of type and region:

Artemisinin Combination Therapy Type Outlook (Revenue, USD Million, 2014 – 2025)

Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate

Artemisinin Combination Therapy Regional Outlook (Revenue, USD Million, 2014 – 2025)

Asia Pacific
- China
- India
- Pakistan
- Indonesia
- Vietnam
Latin America
- Brazil
- Colombia
Middle East & Africa
- Nigeria
- Democratic Republic of Congo
- Mali
- Uganda
- Kenya

Table of Content

Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic Scope & Assumptions
1.4 Region-wise Market Calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising Demand for Artemisinin Combination Therapy (ACT)
3.2.2 Strong product pipeline
3.2.3 Rising Government Initiatives
3.3 Market restraint analysisContinue…………

Sarcoma Drugs Market Competitive Landscape Outlook to 2023

The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. Introduction of targeted therapy has revolutionized treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

For Latest research study : @ https://www.grandviewresearch.com/industry-analysis/sarcoma-drugs-market

Further key findings from the report suggest:

EU5 will remain the second largest market with more than 30% share by 2023. The growth of the segment can be attributed to rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
Eli Lilly’s Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
Companies with late-stage pipeline products for sarcoma are likely to enter the market by 2019 and would capture more than 10.0% of the sarcoma market share in 2023
Drugs with novel targets in early-phase development include Novartis’s Afinitor (mTOR inhibitor), Tesaro’s Zejula (PARP inhibitor), Amgen’s Imlygic (gene therapy), and Pfizer’s Crizotinib (ALK and MET tyrosine kinases inhibitor)
Role of VEGF inhibitors and mTOR inhibitors is under evaluation in multiple early phase trials. However, no statistically significant data has been reported till date

Grand View Research has segmented the global sarcoma drugs market based on treatment type and region:

Sarcoma Drugs Treatment Class Outlook (Revenue, USD Million, 2017 – 2023)

Chemotherapy
Targeted Therapy

Sarcoma Drugs Country Outlook (Revenue, USD Million, 2017 – 2023)

U.S.
U.K.
Germany
France
Italy
Spain
Japan

Table of Content

Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1. Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Soft Tissue Sarcoma (STS)
3.1.2 Bone Sarcoma
3.1.3 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S.,Japan,EU5)
Chapter 4 Global Sarcoma Drugs Market Overview
4.1 Sarcoma Drugs Market Overview
4.1.1 Tyrosine kinase inhibitors (c-KIT, PDGFR, and VEGF inhibitors)
4.1.2 Cell Cycle Inhibitors
4.1.3 mTOR inhibitors
4.2 Market, by Treatment Type
4.3 Market Size and Forecast (2017 – 2023)
4.4 Market Size and Forecast, by Seven Major Markets (2017 – 2023)

Continue………….

Systemic Lupus Erythematosus Market: Business Analysis, Scope, Size, Overview, Forecast 2025

The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.

Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.

The adoption of procurement outsourcing is gaining traction across all sectors and industry verticals. The manufacturing sector has been an early adopter of purchase outsourcing across non-core spend. The emphasis of procurement as a service in manufacturing, typically tends to be on creating and investing in a supply chain organization targeting direct inputs and raw materials. As a result, the adoption of procurement as a service has potentially benefited the manufacturing businesses by reducing their supply chain costs and achieving shorter production times.

For Latest research study : @ https://www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market

Further key findings from the study suggest:

North America was the major contributor for the SLE market revenue in 2017 and is anticipated to rise at a CAGR of 8.1% during the forecast period. This is due to availability of reimbursement and better healthcare infrastructure and accessibility to biologics.
Europe was ranked as the second largest regional market in the SLE market in 2017 and is expected to register a CAGR of 5.5% over the forecast period
Immunosuppressants held the largest share in the market in 2017 due to their low cost and high accessibility, whereas the biologics segment is projected to post the highest CAGR during the same period
In 2017, the oral segment held the dominant share of over 54.0% in the market, followed by the intravenous segment that requires trained medical personnel for administration. Over the forecast years, the latter is poised to expand at a CAGR of 10.4%
Key players in this space include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are anticipated to enter the SLE market.

Grand View Research has segmented the global systemic lupus erythematosus market by drug class, route of administration, and region:

Systemic Lupus Erythematosus Drug Classes Outlook (Revenue, USD Million, 2014 – 2025)

NSAIDs
Corticosteroids
Antimalarials
Immunosuppressants
Biologics

Systemic Lupus Erythematosus Route of Administration Outlook (Revenue, USD Million, 2014 – 2025)

Oral
Intravenous
Subcutaneous

Table of Content

Chapter 1 Report Scope
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates & Forecast Timeline
Chapter 2 Research Methodology
2.1 Model Details
2.1.1 Regression And Variable Analysis
2.2 Information Procurement
2.2.1 List Of Secondary Sources
2.3 List Of Primary Sources
2.4 Purchased Database:
2.5 Gvr’s Internal Database
2.6 Primary Interview Breakup
2.6.1 Data For Primary Interviews, By Sources
2.6.2 Data For Primary Interviews, By Region
Chapter 3 Report Objectives
3.1 Objectives

Continue………….